The 9 most recent market catalysts affecting $RYTM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 28, 2026
Corporate Catalyst
Neutral
Impact 55
Deutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target of $120
Deutsche Bank analyst David Hoang has initiated coverage on Rhythm Pharmaceuticals (RYTM) with a 'Hold' rating and a $120 price target. This event is significant for RYTM as it int…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146
JP Morgan analyst Priyanka Grover maintained an 'Overweight' rating on Rhythm Pharmaceuticals (RYTM) and raised the price target by a modest $1, from $145 to $146. This action sign…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143
Citigroup analyst Samantha Semenkow maintained a 'Buy' rating on Rhythm Pharmaceuticals (RYTM) and raised the price target from $142 to $143. This action signals continued positive…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155
RBC Capital's analyst Lisa Walter has reiterated an 'Outperform' rating for Rhythm Pharmaceuticals and raised the price target from $141 to $155. This action signals continued conf…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160
Citizens analyst Jonathan Wolleben maintained a 'Market Outperform' rating on Rhythm Pharmaceuticals (RYTM) and raised the price target from $155 to $160. This action signals conti…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
Rhythm Pharmaceuticals Announces Preliminary Results From Ongoing Phase 2 Trial Evaluating RM-718 In Patients With Acquired Hypothalamic Obesity; BMI Reductions Consistent With Setmelanotide And Bivamelagon; Sees -11.6% Mean Reduction In BMI From Baseline At Week
Rhythm Pharmaceuticals released encouraging preliminary Phase 2 data for RM-718, its drug candidate for acquired hypothalamic obesity (HO). The -11.6% mean BMI reduction is signifi…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 85
Rhythm Pharmaceuticals shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating and announced a $145 price target.
This headline represents a significant corporate catalyst for Rhythm Pharmaceuticals. An 'Overweight' rating from a major investment bank like JP Morgan, coupled with a high price …
Jul 27, 2026
Corporate Catalyst
Neutral
Impact 65
JP Morgan Initiates Coverage On Rhythm Pharmaceuticals with Overweight Rating, Announces Price Target of $145
JP Morgan's initiation of coverage on Rhythm Pharmaceuticals with an 'Overweight' rating and a $145 price target is a significant event for the company. Analyst initiations, especi…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.